Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q1 2025 · 10-Q
Revenue$2.00M$2.00Mno prior Q1 2024 on file Net Income-$7.64M-$7.64MN/M vs Q1 2024 EPS Diluted-$0.19-$0.19N/M vs Q1 2024 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Operating Cash Flow-$3,519,000N/M Free Cash Flowderived-$3,522,000N/M Margins · derivedGross margin0.7%
Operating margin-225.0%
Net margin-382.1%
ended Mar 31, 2025 · filed May 15, 2025 · 45 d after period end